TTNP

About Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union. This implant provides maintenance treatment for clinically stable individuals struggling with opioid use disorder. Beyond Probuphine, Titan Pharmaceuticals is advancing several pipeline candidates. Among these is the kappa opioid agonist peptide program (TP-2021), which utilizes the ProNeura technology to address chronic pruritus. Another key development is a nalmefene implant program, aimed at preventing opioid relapse in patients after detoxification from opioid use disorder. Furthermore, the company is exploring other applications for its ProNeura platform, including a single implant for HIV prevention and a contraceptive option for women and adolescent girls. Established in 1992, Titan Pharmaceuticals operates from its base in South San Francisco, California.

CEO: Weei Jye Chay
IPO Date: Jan 18, 1996

Market Data

Open: $2.55
High: $2.69
Low: $2.30
Volume: 131.9K
Avg Volume: 98.6K
52W High: $15.15
52W Low: $2.33

Valuation

Market Cap: $3.1M
Enterprise Value: $-67M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-3.9M
Revenue: $0
Net Income: $-4.7M
Cash: $2.8M
Debt: $0

Events

EarningsJan 1

actual -0.57439